Skip to Main Content
An official website of the United States government
Login Change: CDAS is now using the NIH Researcher Auth Service (RAS) to manage our existing login options. When logging into CDAS, you will be taken to RAS, where you can select your preferred login provider to access CDAS.

Browse Lab Results > 2009-0553

Trial Summary

About CDAS Project, PI, Publications: Epigenotyping in Peripheral Blood Cell DNA and Risk of Breast Cancer

Datasets

Site: Breast

Inclusion Criteria:

  • Intervention Arm Females
  • No Prior History of Any Cancer
  • No Erroneous/Unconfirmable/In situ Breast Cancers
  • No Rare Cancers
  • No Reports of Any Cancer During Trial (other than breast for cases)
  • In 2005-007 Genotype Population
  • With Unchanged Case Definition
  • Extracted DNA Available or T0 Buffy Coat
  • Pre-Exit Extracted DNA/T0 Buffy Coat
  • Pre-Exit Extracted DNA/T0 Buffy Coat 1+ Years Pre-Dx (Cases)
  • Cases Limited to Target Group

Matching Factors:

  • Age at Randomization (5 year intervals)
  • Fiscal Year of Randomization (<=1997, >1997)
  • DNA Material Type (Source/Extracted)
  • Study Year of Blood Draw

Match Ratio: 1:1

Match Technique: Frequency matching only non-cases as controls.

Additional Matching Comments: Most distal extracted DNA was taken for cases, if available. T0 buffy coat was taken for the remaining cases.

Analytes:

  • 2'-deoxyguanine concentration
  • 5-methyl-22-deoxycytidine concentration
  • 5-methyl-22-deoxycytidine to 2'-deoxyguanine percent
  • 5-methyl-22-deoxycytidine to 2'-deoxyguanine ratio
  • Average 2'-deoxyguanine concentration
  • Average 5-methyl-22-deoxycytidine
  • Average 5-methyl-22-deoxycytidine to 2'-deoxyguanine percent

Number of Cases: 430

Number of Controls: 426